EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells

Dedy Hermansyah, Siti Syarifah, Adi Muradi Muhar, Nur Dina Amalina

Trends in Sciences · 25.08.2026 · 24 (1) · 14177

DOI: 10.48048/tis.2027.14177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Sciences, online erschienen am 25.08.2026. Verfasst von Dedy Hermansyah und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer stem cells (BCSCs) represent a critical population responsible for tumor recurrence, metastasis, and therapeutic resistance. Despite advances in immunotherapy, targeting BCSCs remains challenging due to their immune evasion mechanisms and limited T cell infiltration. To investigate the potential of paclitaxel-conditioned mesenchymal stem cells (MSCs) in enhancing T cell activation and cytotoxicity against CD44⁺/CD24⁻ breast cancer stem cells. BCSCs were isolated from MDA-MB-231 cells using magnetic-activated cell sorting (MACS) and characterized by flow cytometry. MSCs derived from umbilical cord blood were treated with paclitaxel (10 - 20 μg/mL) for 72 h to generate conditioned medium (CM-MSCs-Pax). CD8+ T cells were isolated from tumor-bearing BALB/c mice and activated using CM-MSCs-Pax. T cell activation was assessed by IL2RA (CD25) expression via qRT-PCR. Co-culture experiments evaluated cytotoxicity against BCSCs using the MTT assay, and molecular mechanisms were examined by analyzing caspase-3 and PD-L1 expression. MACS sorting successfully enriched CD44⁺/CD24⁻ BCSCs to 80.7% purity. Paclitaxel treatment significantly enhanced MSC secretion of IL-6, TNF-α, and IL-10 in conditioned medium. CM-MSCs-Pax treatment increased T cell activation, demonstrated by elevated IL2RA expression. Co-culture of activated T cells with BCSCs at a 10:1 ratio reduced BCSC viability to 9.68% at 72 h compared to 30.20% with unactivated T cells. This enhanced cytotoxicity was associated with increased caspase-3 expression and reduced PD-L1 expression in BCSCs. Paclitaxel-conditioned MSCs create a pro-inflammatory microenvironment that enhances T cell activation and cytotoxicity against BCSCs. This novel approach combining chemotherapy conditioning with immunotherapy represents a promising strategy for targeting therapy-resistant breast cancer stem cell populations. HIGHLIGHTS Paclitaxel-conditioned MSCs (CM-MSCs-Pax) enhance CD8+ T cell activation against breast cancer stem cells (BCSCs). CM-MSCs-Pax increases pro-inflammatory cytokine secretion (IL-6, TNF-α, IL-10). Activated T cells exhibit significantly enhanced cytotoxicity against CD44+/CD24− BCSC viability decreases to ~9.7% at 72 h with CM-MSCs-Pax–activated T cells. Enhanced killing is associated with increased caspase-3 and reduced PD-L1 expression. Chemotherapy-conditioned MSCs offer a promising strategy to overcome BCSC immune resistance. GRAPHICAL ABSTRACT

Zitieren

APA

Hermansyah, D., Syarifah, S., Muhar, A. M., & Amalina, N. D. (2026). Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells. Trends in Sciences, 24(1), 14177. https://doi.org/10.48048/tis.2027.14177

Vancouver

Hermansyah D, Syarifah S, Muhar AM, Amalina ND. Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells. Trends in Sciences. 2026;24(1):14177. doi:10.48048/tis.2027.14177

BibTeX
@article{Hermansyah2026,
  author = {Hermansyah, Dedy and Syarifah, Siti and Muhar, Adi Muradi and Amalina, Nur Dina},
  title = {Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells},
  journal = {Trends in Sciences},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {14177},
  doi = {10.48048/tis.2027.14177}
}
Kostenlos starten →